摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-N-(2-aminoindan-5-yl)-6-methyl-4'-trifluoromethyl-1,1'-biphenyl-2-carboxamide | 321352-56-1

中文名称
——
中文别名
——
英文名称
(R)-N-(2-aminoindan-5-yl)-6-methyl-4'-trifluoromethyl-1,1'-biphenyl-2-carboxamide
英文别名
[1,1'-biphenyl]-2-carboxamide, N-[(2R)-2-amino-2,3-dihydro-1H-inden-5-yl]-6-methyl-4'-(trifluoromethyl)-;(R)-N-(2-aminoindan-5-yl)-6-methyl-4'-trifluoromethylbiphenyl-2-carboxamide;N-[(2R)-2-amino-2,3-dihydro-1H-inden-5-yl]-3-methyl-2-[4-(trifluoromethyl)phenyl]benzamide
(R)-N-(2-aminoindan-5-yl)-6-methyl-4'-trifluoromethyl-1,1'-biphenyl-2-carboxamide化学式
CAS
321352-56-1
化学式
C24H21F3N2O
mdl
——
分子量
410.439
InChiKey
RNNQNFVSJBMSFH-LJQANCHMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.1
  • 重原子数:
    30
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.21
  • 拓扑面积:
    55.1
  • 氢给体数:
    2
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    bis-(2-chloro-ethyl)-carbamic acid methyl ester(R)-N-(2-aminoindan-5-yl)-6-methyl-4'-trifluoromethyl-1,1'-biphenyl-2-carboxamideN,N-二异丙基乙胺 作用下, 反应 3.0h, 以14%的产率得到4-{5-[(6-Methyl-4''-trifluoromethyl-biphenyl-2-carbonyl)-amino]-indan-2-yl}-piperazine-1-carboxylic acid methyl ester
    参考文献:
    名称:
    Diaminoindanes as Microsomal Triglyceride Transfer Protein Inhibitors
    摘要:
    The synthesis and biological activities of biarylamide-substituted diaminoindanes as microsomal triglyceride transfer protein (MTP) inhibitors are described. One of the more potent compounds, 8aR, inhibited both the secretion of apoB from Hep G2 cells and the MTP-mediated transfer of triglycerides between synthetic acceptor and donor liposomes with IC50 values of 0.7 and 70 nM, respectively. In normolipidemic rats and dogs, oral administration of 8aR dose-dependently reduced both plasma triglycerides and total cholesterol. Moreover, in rats and dogs, 8aR also prevented the postprandial rise in plasma triglycerides following a bolus administration of a fat load. Because MTP inhibitors decrease very low density lipoprotein assembly in the liver, the potential for hepatic lipid accumulation was evaluated. In normolipidemic rats, hepatic cholesterol and triglyceride contents were dose-dependently increased by 8aR. However, hepatic lipid accumulation resulted in negligible change in total liver weight and was reversible after withdrawal of the compound.
    DOI:
    10.1021/jm010294e
  • 作为产物:
    参考文献:
    名称:
    Diaminoindanes as Microsomal Triglyceride Transfer Protein Inhibitors
    摘要:
    The synthesis and biological activities of biarylamide-substituted diaminoindanes as microsomal triglyceride transfer protein (MTP) inhibitors are described. One of the more potent compounds, 8aR, inhibited both the secretion of apoB from Hep G2 cells and the MTP-mediated transfer of triglycerides between synthetic acceptor and donor liposomes with IC50 values of 0.7 and 70 nM, respectively. In normolipidemic rats and dogs, oral administration of 8aR dose-dependently reduced both plasma triglycerides and total cholesterol. Moreover, in rats and dogs, 8aR also prevented the postprandial rise in plasma triglycerides following a bolus administration of a fat load. Because MTP inhibitors decrease very low density lipoprotein assembly in the liver, the potential for hepatic lipid accumulation was evaluated. In normolipidemic rats, hepatic cholesterol and triglyceride contents were dose-dependently increased by 8aR. However, hepatic lipid accumulation resulted in negligible change in total liver weight and was reversible after withdrawal of the compound.
    DOI:
    10.1021/jm010294e
点击查看最新优质反应信息

文献信息

  • Carboxamides useful as inhinitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion
    申请人:——
    公开号:US20030109700A1
    公开(公告)日:2003-06-12
    1 Compounds of formula (1) wherein R 2 —C, R 3 —C, R 4 —C or R 5 —C may be replaced by N; and wherein n is 1, 2 or 3; R 1 is aryl, heteroaryl or (aryl or heteroaryl)-lower alkoxy; R 2 , R 3 , R 4 and R 5 are independently hydrogen, lower alkyl, lower alkoxy, halo, trifluoromethyl or cyano; R 6 is (i) or (ii) m is 1, 2 or 3; R 7 is hydrogen, lower alkyl (aryl or heteroaryl)-lower alkyl, lower alkoxy, (aryl or heteroaryl)-lower alkoxy, hydroxy, oxo, lower alkylenedioxy or lower alkanoyloxy; W is O, S or NR 8 ; R 8 is —COR a , (iii), —COOR d , —SO 2 R e , hydrogen, optionally substituted lower alkyl, aryl, heteroaryl or (aryl or heteroaryl)-lower alkyl; R a , R d and R e , are independently optionally substituted lower alkyl, cycloalkyl, adamantyl, aryl, heteroaryl or (aryl or heteroaryl)-lower alkyl; R b and R c are independently hydrogen, cycloalkyl, optionally substituted lower alkyl, aryl, heteroaryl or (aryl or heteroaryl) lower alkyl; or R b and R c together represent lower alkylene; and pharmaceutically acceptable salts thereof; and enantiomers thereof; which are useful as inhibitors of microsomal triglyceride transfer protein (MTP) and of apolipoprotein B (apoB) secretion.
    式(1)的化合物中,其中R2—C,R3—C,R4—C或R5—C可以被N取代;其中n为1、2或3;R1为芳基,杂环芳基或(芳基或杂环芳基)-较低烷氧基;R2、R3、R4和R5独立地为氢、较低烷基、较低烷氧基、卤素、三氟甲基或氰基;R6为(i)或(ii)m为1、2或3;R7为氢、较低烷基(芳基或杂环芳基)-较低烷基、较低烷氧基、(芳基或杂环芳基)-较低烷氧基、羟基、氧代、较低烷二氧基或较低烷酰氧基;W为O、S或NR8;R8为—CORa、(iii)、—COORd、—SO2Re、氢、可选择取代的较低烷基、芳基、杂环芳基或(芳基或杂环芳基)-较低烷基;Ra、Rd和Re独立地为可选择取代的较低烷基、环烷基、脱氢脂肪基、芳基、杂环芳基或(芳基或杂环芳基)-较低烷基;Rb和Rc独立地为氢、环烷基、可选择取代的较低烷基、芳基、杂环芳基或(芳基或杂环芳基)较低烷基;或Rb和Rc一起代表较低烷基;以及其药学上可接受的盐;以及其对映体;它们可用作微粒体三酰甘油转移蛋白(MTP)和载脂蛋白B(apoB)分泌的抑制剂。
  • Identification and structure–activity relationships of ortho-biphenyl carboxamides as potent Smoothened antagonists inhibiting the Hedgehog signaling pathway
    作者:Stefan Peukert、Rishi K. Jain、Adrian Geisser、Yingchuan Sun、Rui Zhang、Aaron Bourret、Adam Carlson、Jennifer DaSilva、Arun Ramamurthy、Joseph F. Kelleher
    DOI:10.1016/j.bmcl.2008.11.096
    日期:2009.1
    prepared as inhibitors of microsomal triglyceride transfer protein (MTP) have been identified as novel inhibitors of the Hedgehog signaling pathway. Structure–activity relationship studies for this class of compounds reduced MTP inhibitory activity and led to low nanomolar Hedgehog inhibitors. Binding assays revealed that the compounds act as antagonists of Smoothened and show cross-reactivity for both
    最初作为微粒体甘油三酸酯转移蛋白(MTP)抑制剂制备的邻-联苯羧酰胺已被鉴定为Hedgehog信号通路的新型抑制剂。这类化合物的结构-活性关系研究降低了MTP抑制活性,并导致了低纳摩尔的刺猬抑制剂。结合测定显示该化合物充当平滑剂的拮抗剂,并显示出对人和小鼠受体的交叉反应性。
  • Amino-benzocycloalkane derivatives
    申请人:Novartis AG
    公开号:US06197798B1
    公开(公告)日:2001-03-06
    Compounds of the formula I wherein R2—C, R3—C, R4—C or R5—C may be replaced by N; and wherein n is 1, 2 or 3; R1 is aryl, cycloalkyl or heterocyclyl; R2, R3, R4 and R5 are independently hydrogen, optionally substituted alkyl, halo, amino, substituted amino, trifluoromethyl, cyano, carboxyl, alkoxycarbonyl, aralkoxycarbonyl, (alkyl, aryl or aralkyl)-thio, (alkyl, aryl or aralkyl)-oxy, acyloxy, (alkyl, aryl or aralkyl)-aminocarbonyloxy; or any two of R2, R3, R4 and R5 at adjacent positions are alkylenedioxy; R6 is hydrogen, optionally substituted alkyl, amino, substituted amino, acylamino, wherein Ra is hydrogen or optionally substituted alkyl, Rb and Rc are independently hydrogen, optionally substituted alkyl, cycloalkyl, aryl or heterocyclyl; or Rb and Rc together represent lower alkylene or lower alkylene interrupted by O, S, or N—(H, alkyl or aralkyl); Rd is optionally substituted alkyl, cycloalkyl, aryl or heterocyclyl; and Re is optionally substituted alkyl, aryl, heterocyclyl, cycloalkyl, amino or substituted amino; and pharmaceutically acceptable salts thereof; and enantiomers thereof; which are useful as inhibitors of microsomal triglyceride transfer protein (MTP) and of apolipoprotein B (ApoB) secretion.
    根据您的要求,以下是公式I化合物的中文翻译: 化合物具有公式I,其中R2—C、R3—C、R4—C或R5—C可以被N取代;并且其中n为1、2或3;R1为芳基、环烷基或杂环基;R2、R3、R4和R5独立地为氢、可选地取代的烷基、卤素、氨基、取代氨基、三氟甲基、氰基、羧基、烷氧羰基、芳烷氧羰基、(烷基、芳基或芳烷基)硫基、(烷基、芳基或芳烷基)氧基、酰氧基、(烷基、芳基或芳烷基)氨基甲氧基;或者R2、R3、R4和R5中任意两个相邻位置的为烷基亚甲基二氧基;R6为氢、可选地取代的烷基、氨基、取代氨基、酰氨基,其中Ra为氢或可选地取代的烷基,Rb和Rc独立地为氢、可选地取代的烷基、环烷基、芳基或杂环基;或者Rb和Rc共同代表低碳烯基或由O、S或N—(H、烷基或芳烷基)打断的低碳烯基;Rd为可选地取代的烷基、环烷基、芳基或杂环基;Re为可选地取代的烷基、芳基、杂环基、环烷基、氨基或取代氨基;以及药用可接受的盐;以及它们的对映体;这些化合物可用作微粒体甘油三酯转移蛋白(MTP)和载脂蛋白B(ApoB)分泌的抑制剂。
  • Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion
    申请人:Ksander Gary Michael
    公开号:US06878707B2
    公开(公告)日:2005-04-12
    Compounds of formula (I) wherein R 2 —C, R 3 —C, R 4 —C or R 5 —C may be replaced by N; and wherein n is 1, 2 or 3; R 1 is aryl, heteroaryl or (aryl or heteroaryl)-lower alkoxy; R 2 , R 3 , R 4 and R 5 are independently hydrogen, lower alkyl, lower alkoxy, halo, trifluoromethyl or cyano; R 6 is (i) or (ii) m is 1, 2 or 3; R 7 is hydrogen, lower alkyl (aryl or heteroaryl)-lower alkyl, lower alkoxy, (aryl or heteroaryl)-lower alkoxy, hydroxy, oxo, lower alkylenedioxy or lower alkanoyloxy; W is O, S or NR 8 ; R 8 is —COR a , (iii), —COOR d , —SO 2 R e , hydrogen, optionally substituted lower alkyl, aryl, heteroaryl or (aryl or heteroaryl)-lower alkyl; R a , R d and R e are independently optionally substituted lower alkyl, cycloalkyl, adamantyl, aryl, heteroaryl or (aryl or heteroaryl)-lower alkyl; R b and R c are independently hydrogen, cycloalkyl, optionally substituted lower alkyl, aryl, heteroaryl or (aryl or heteroaryl) lower alkyl; or R b and R c together represent lower alkylene; and pharmaceutically acceptable salts thereof; and enantiomers thereof; which are useful as inhibitors of microsomal triglyceride transfer protein (MTP) and of apolipoprotein B (apoB) secretion.
    化合物的公式(I),其中R2-C,R3-C,R4-C或R5-C可以被N替换;其中n为1、2或3; R1为芳基、杂环芳基或(芳基或杂环芳基)-较低烷氧基; R2、R3、R4和R5独立地为氢、较低烷基、较低烷氧基、卤素、三氟甲基或氰基; R6为(i)或(ii),m为1、2或3; R7为氢、较低烷基(芳基或杂环芳基)-较低烷基、较低烷氧基、(芳基或杂环芳基)-较低烷氧基、羟基、氧代、较低烷二氧基或较低烷酰氧基; W为O、S或NR8; R8为-CORa、(iii)、-COORd、-SO2Re、氢、可选择性取代的较低烷基、芳基、杂环芳基或(芳基或杂环芳基)-较低烷基; Ra、Rd和Re独立地为可选择性取代的较低烷基、环烷基、金刚烷基、芳基、杂环芳基或(芳基或杂环芳基)-较低烷基; Rb和Rc独立地为氢、环烷基、可选择性取代的较低烷基、芳基、杂环芳基或(芳基或杂环芳基)较低烷基;或Rb和Rc共同代表较低烷基;以及其药学上可接受的盐;和其对映异构体;这些化合物可用作微粒体甘油三酯转移蛋白(MTP)和载脂蛋白B(apoB)分泌的抑制剂。
  • CARBOXAMIDES USEFUL AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND OF APOLIPOPROTEIN B SECRETION
    申请人:Novartis AG
    公开号:EP1259484B1
    公开(公告)日:2005-05-18
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐